What changed
What changedCVS Health reported $108.4 billion in revenue for the third quarter of 2026 and announced plans to split into two separate companies. For shareholders, this means a transition to two independent public companies, specialized in healthcare solutions and retail pharmacy.

Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
CVS Health intends to separate into two independent, publicly traded companies, a process expected to be completed in the first half of 2028.
Said November 4, 2026 · Period named: first half of 2028 · Source · Our article
Not yet checked against later reports.
The company expects to complete the separation in the first half of 2028, subject to conditions including board approval, effectiveness of a Form 10 registration statement, and tax-free treatment confirmation.
Said November 4, 2026 · Period named: first half of 2028 · Source · Our article
Not yet checked against later reports.
The company expects the separation into two independent companies to be completed in the first half of 2028, subject to customary conditions including board approval and effectiveness of a Form 10 registration statement.
Said November 4, 2026 · Period named: first half of 2028 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| August 17, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 120,390,157 | $10,316,232,599 | -2.3% | Q3 2026 |
| State Street | 60,087,270 | $5,148,878,166 | -0.3% | Q3 2026 |
| Wellington Management | 36,682,829 | $3,143,351,616 | +8.5% | Q3 2026 |
| Geode Capital Management | 30,921,045 | $2,638,142,619 | +3.4% | Q3 2026 |
| Fidelity (FMR) | 24,881,207 | $2,132,070,581 | -14.0% | Q3 2026 |
| Capital Research Global Investors | 21,853,140 | $1,872,682,211 | -10.2% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 18,038,922 | $1,866,126,481 | — | Q2 2026 |
| Renaissance Technologies | 2,724,053 | $233,424,102 | +517.7% | Q3 2026 |
| Millennium Management | 1,495,249 | $128,127,887 | -30.9% | Q3 2026 |
| D. E. Shaw & Co. | 1,028,148 | $88,102,002 | -25.6% | Q3 2026 |
| Citadel Advisors | 815,797 | $69,905,645 | -83.0% | Q3 2026 |
| Bridgewater Associates | 378,152 | $32,403,845 | -14.2% | Q3 2026 |
| Two Sigma Investments | 134,635 | $11,536,873 | — | Q3 2026 |
| T. Rowe Price | 21,663,186 | $1,856,319 | -10.5% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.